{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1390001288114711680.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.2958/suizo.33.944"}},{"identifier":{"@type":"URI","@value":"https://www.jstage.jst.go.jp/article/suizo/33/6/33_944/_pdf"}},{"identifier":{"@type":"NAID","@value":"130007569045"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2019124598"}}],"dc:title":[{"@language":"ja","@value":"膵腫瘍におけるBRCA経路遺伝子変異とその臨床的意義"},{"@language":"en","@value":"BRCA-pathway gene mutations in pancreatic neoplasms and their clinicopathological relevance"}],"dc:language":"ja","description":[{"type":"abstract","notation":[{"@language":"en","@value":"<p><i>BRCA1</i>, <i>BRCA2</i>, and <i>PALB2</i> are BRCA-pathway genes whose products are associated with homologous recombination repair of double strand breaks of DNA. Germline mutations of BRCA-pathway genes are known to elevate the risk for development of pancreatic cancer. However, BRCA-pathway gene mutations in tumors are associated with susceptibility to cisplatin and the poly ADP ribose inhibitor, which may have a dramatic therapeutic effect. We investigated BRCA-pathway gene mutations in sporadic pancreatic ductal adenocarcinomas (PDACs), familial PDACs, and pancreatic acinar cell carcinomas, and found that 2.4%, 9.3%, and 43% of sporadic PDACs, familial PDACs, and acinar cell carcinomas, respectively, harbored pathogenic mutations, i.e., frameshifts or nonsense mutations of BRCA-pathway genes. Patients with sporadic PDACs with pathogenic mutations and variants of unknown significance had longer survival than those with PDACs with benign variants or no mutations. Complete remission of multiple liver metastases from a pancreatic acinar cell carcinoma with a <i>BRCA2</i> mutation by treatment with cisplatin was observed. Pancreatic cancers with BRCA-pathway gene mutations are likely to respond well to certain drugs, hence identifying patients with such tumors is particularly important in the era of genomic medicine.</p>"},{"@language":"ja","@value":"<p><i>BRCA1</i>，<i>BRCA2</i>，<i>PALB2</i>はBRCA経路遺伝子と呼ばれ，その産物はDNA二重鎖切断の相同組換え修復に関与する．BRCA経路遺伝子の生殖系列変異は膵癌発症のリスクを高め，また，BRCA経路遺伝子異常を持つ癌腫は白金系薬剤やPARP阻害剤に特異的に感受性が高く，臨床的に劇的な効果を見ることがある．我々は孤発性膵管癌，家族性膵癌，膵腺房細胞癌においてBRCA経路遺伝子変異を検索し，それぞれ2.4%，9.3%，43%に明らかな病原性変異を認めた．孤発性膵管癌例においては病原性あるいは効果不明のBRCA経路遺伝子変異を持つ患者群が有意に予後良好であった．また，BRCA経路遺伝子変異を持つ膵腺房細胞癌の多発肝転移がcisplatin投与で完全寛解した例を経験した．BRCA経路遺伝子変異を持つ膵腫瘍を見出すことは今後展開されるゲノム医療上極めて意義深いと考えられる．</p>"}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1420001326219192704","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"30282122"},{"@type":"NRID","@value":"1000030282122"},{"@type":"NRID","@value":"9000001537092"},{"@type":"NRID","@value":"9000002893835"},{"@type":"NRID","@value":"9000005710049"},{"@type":"NRID","@value":"9000404826418"},{"@type":"NRID","@value":"9000356585984"},{"@type":"NRID","@value":"9000014156951"},{"@type":"NRID","@value":"9000414093300"},{"@type":"NRID","@value":"9000258223773"},{"@type":"NRID","@value":"9000350631444"},{"@type":"NRID","@value":"9000409999961"},{"@type":"NRID","@value":"9000241789383"},{"@type":"NRID","@value":"9000369354050"},{"@type":"NRID","@value":"9000410622607"},{"@type":"NRID","@value":"9000414223686"},{"@type":"NRID","@value":"9000398822301"},{"@type":"NRID","@value":"9000010332406"},{"@type":"NRID","@value":"9000273748262"},{"@type":"NRID","@value":"9000011192529"},{"@type":"NRID","@value":"9000402273413"},{"@type":"NRID","@value":"9000000699802"},{"@type":"NRID","@value":"9000001973062"},{"@type":"NRID","@value":"9000008876024"},{"@type":"NRID","@value":"9000263062929"},{"@type":"NRID","@value":"9000021923732"},{"@type":"NRID","@value":"9000403105477"},{"@type":"NRID","@value":"9000002917303"},{"@type":"NRID","@value":"9000414841240"},{"@type":"NRID","@value":"9000413948878"},{"@type":"NRID","@value":"9000001537082"},{"@type":"NRID","@value":"9000018530306"},{"@type":"NRID","@value":"9000020406445"},{"@type":"NRID","@value":"9000256621914"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/read0052218"}],"foaf:name":[{"@language":"ja","@value":"古川 徹"},{"@language":"en","@value":"FURUKAWA Toru"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Histopathology, Tohoku University Graduate School of Medicine"},{"@language":"ja","@value":"東北大学大学院医学系研究科病理形態学分野"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"09130071"},{"@type":"LISSN","@value":"09130071"},{"@type":"EISSN","@value":"18812805"}],"prism:publicationName":[{"@language":"en","@value":"Suizo"},{"@language":"ja","@value":"膵臓"},{"@language":"en","@value":"Journal of the Japan Pancreas Society"},{"@language":"en","@value":"Suizo"},{"@language":"en","@value":"J. JPN. PANC. SOC."},{"@language":"ja","@value":"膵臓"}],"dc:publisher":[{"@language":"en","@value":"Japan Pancreas Society"},{"@language":"ja","@value":"一般社団法人 日本膵臓学会"}],"prism:publicationDate":"2018-12-25","prism:volume":"33","prism:number":"6","prism:startingPage":"944","prism:endingPage":"948"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","url":[{"@id":"https://www.jstage.jst.go.jp/article/suizo/33/6/33_944/_pdf"},{"@id":"https://search.jamas.or.jp/link/ui/2019124598"}],"availableAt":"2018-12-25","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=%E8%86%B5%E8%87%93%E7%99%8C","dc:title":"膵臓癌"},{"@id":"https://cir.nii.ac.jp/all?q=%3Ci%3EBRCA1%3C/i%3E","dc:title":"<i>BRCA1</i>"},{"@id":"https://cir.nii.ac.jp/all?q=%3Ci%3EBRCA2%3C/i%3E","dc:title":"<i>BRCA2</i>"},{"@id":"https://cir.nii.ac.jp/all?q=%3Ci%3EPALB2%3C/i%3E","dc:title":"<i>PALB2</i>"},{"@id":"https://cir.nii.ac.jp/all?q=%E3%82%B2%E3%83%8E%E3%83%A0","dc:title":"ゲノム"},{"@id":"https://cir.nii.ac.jp/all?q=Pancreatic%20cancer","dc:title":"Pancreatic cancer"},{"@id":"https://cir.nii.ac.jp/all?q=%3Ci%3EBRCA1%3C/i%3E","dc:title":"<i>BRCA1</i>"},{"@id":"https://cir.nii.ac.jp/all?q=%3Ci%3EBRCA2%3C/i%3E","dc:title":"<i>BRCA2</i>"},{"@id":"https://cir.nii.ac.jp/all?q=%3Ci%3EPALB2%3C/i%3E","dc:title":"<i>PALB2</i>"},{"@id":"https://cir.nii.ac.jp/all?q=Genome","dc:title":"Genome"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050282677747624960","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancerassociated genes in pancreatic ductal adenocarcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011142937863040","@type":"Article","resourceType":"preprint","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Analysis of protein-coding genetic variation in 60,706 humans"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145698840064","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Germline mutations in Japanese familial pancreatic cancer patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292618854075904","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565166809472512","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574093681701248","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prospective Risk of Pancreatic Cancer in Familial Pancreatic Cancer Kindreds"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094674675456","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"OncoKB: A Precision Oncology Knowledge Base"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574096516332032","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pancreatic cancer as a sentinel for hereditary cancer predisposition"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855224121697664","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419470761728","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320004331008","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known <i>BRCA</i> Mutation: Clinical Descriptors, Treatment Implications, and Future Directions"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270015229824","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prevalence of Germline Mutations in Cancer Predisposition Genes in Patients With Pancreatic Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1390302016256051584","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A case of pancreatic acinar cell carcinoma with temporally changing morphology and internal characteristics effectively treated by neoadjuvant chemotherapy"},{"@language":"ja","@value":"経時的に形態・内部性状が変化した膵腺房細胞癌に対して，術前補助化学療法が奏効した1切除例"}]},{"@id":"https://cir.nii.ac.jp/crid/1390849376468299520","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two patients with postoperative recurrence of pancreatic acinar cell carcinoma successfully treated by FOLFIRINOX"},{"@language":"ja","@value":"術後再発にFOLFIRINOX療法が著効した膵腺房細胞癌の2例"}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:2006988119"},{"@type":"CROSSREF","@value":"10.2958/suizo.33.944"},{"@type":"CIA","@value":"130007569045"},{"@type":"OPENAIRE","@value":"doi_dedup___::494edec57ed889195582dfb401b7f1e3"},{"@type":"CROSSREF","@value":"10.2958/suizo.39.348_references_DOI_HOtregc3sL7nOfP7iVxpF0uX8tN"},{"@type":"CROSSREF","@value":"10.2958/suizo.35.418_references_DOI_HOtregc3sL7nOfP7iVxpF0uX8tN"}]}